Leah H Biller1, Miki Horiguchi2, Hajime Uno2, Chinedu Ukaegbu3, Sapna Syngal1, Matthew B Yurgelun4. 1. Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Brigham & Women's Hospital, Boston, Massachusetts. 2. Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 3. Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Brigham & Women's Hospital, Boston, Massachusetts. Electronic address: matthew_yurgelun@dfci.harvard.edu.
Abstract
BACKGROUND & AIMS: Lynch syndrome (LS) is associated with increased risks of various gastrointestinal, gynecologic, genitourinary, and other cancers. Many clinical practice guidelines recommend that LS carriers' screening strategies be devised based on their family history of various cancers, in addition to age-, sex-, and gene-specific considerations. The aim of this study was to examine the association between family history and other clinical factors with LS carriers' histories of various cancers. METHODS: Two cohorts of LS carriers were analyzed: a laboratory-based cohort of consecutively ascertained individuals undergoing germline LS testing and a clinic-based cohort of LS carriers undergoing clinical care at an academic medical center. Multivariable logistic regression was performed to assess clinical factors associated with LS carriers' histories of various cancers/neoplasms. Familial burden was defined as LS carriers' aggregate number of first-/second-degree relatives with a history of a given malignancy. RESULTS: Multivariable analysis of the laboratory-based cohort (3828 LS carriers) identified familial burden as being incrementally associated with LS carriers' personal history of endometrial (odds ratio [OR], 1.37 per affected first-/second-degree relative; 95% confidence interval [CI], 1.21-1.56), urinary tract (OR, 2.72; 95% CI, 2.02-3.67), small bowel (OR, 3.17; 95% CI, 1.65-6.12), gastric (OR, 1.93; 95% CI, 1.24-3.02), and pancreaticobiliary cancers (OR, 2.10; 95% CI, 1.21-3.65) and sebaceous neoplasms (OR, 7.39; 95% CI, 2.71-20.15). Multivariable analysis of the clinic-based cohort (607 LS carriers) confirmed a significant association of familial burden of endometrial and urinary tract cancers. CONCLUSIONS: Familial burden - in addition to age, sex, and specific LS gene - should be used to assess LS carriers' risks of specific cancers and guide decision-making about organ-specific surveillance.
BACKGROUND & AIMS: Lynch syndrome (LS) is associated with increased risks of various gastrointestinal, gynecologic, genitourinary, and other cancers. Many clinical practice guidelines recommend that LS carriers' screening strategies be devised based on their family history of various cancers, in addition to age-, sex-, and gene-specific considerations. The aim of this study was to examine the association between family history and other clinical factors with LS carriers' histories of various cancers. METHODS: Two cohorts of LS carriers were analyzed: a laboratory-based cohort of consecutively ascertained individuals undergoing germline LS testing and a clinic-based cohort of LS carriers undergoing clinical care at an academic medical center. Multivariable logistic regression was performed to assess clinical factors associated with LS carriers' histories of various cancers/neoplasms. Familial burden was defined as LS carriers' aggregate number of first-/second-degree relatives with a history of a given malignancy. RESULTS: Multivariable analysis of the laboratory-based cohort (3828 LS carriers) identified familial burden as being incrementally associated with LS carriers' personal history of endometrial (odds ratio [OR], 1.37 per affected first-/second-degree relative; 95% confidence interval [CI], 1.21-1.56), urinary tract (OR, 2.72; 95% CI, 2.02-3.67), small bowel (OR, 3.17; 95% CI, 1.65-6.12), gastric (OR, 1.93; 95% CI, 1.24-3.02), and pancreaticobiliary cancers (OR, 2.10; 95% CI, 1.21-3.65) and sebaceous neoplasms (OR, 7.39; 95% CI, 2.71-20.15). Multivariable analysis of the clinic-based cohort (607 LS carriers) confirmed a significant association of familial burden of endometrial and urinary tract cancers. CONCLUSIONS: Familial burden - in addition to age, sex, and specific LS gene - should be used to assess LS carriers' risks of specific cancers and guide decision-making about organ-specific surveillance.
Authors: N Stjepanovic; L Moreira; F Carneiro; F Balaguer; A Cervantes; J Balmaña; E Martinelli Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: Swetlana Ladigan-Badura; Deepak B Vangala; Christoph Engel; Karolin Bucksch; Robert Hueneburg; Claudia Perne; Jacob Nattermann; Verena Steinke-Lange; Nils Rahner; Hans K Schackert; Jürgen Weitz; Matthias Kloor; Judith Kuhlkamp; Huu Phuc Nguyen; Gabriela Moeslein; Christian Strassburg; Monika Morak; Elke Holinski-Feder; Reinhard Buettner; Stefan Aretz; Markus Loeffler; Wolff Schmiegel; Christian Pox; Karsten Schulmann Journal: Int J Cancer Date: 2020-10-13 Impact factor: 7.396
Authors: Elena M Stoffel; Pamela B Mangu; Stephen B Gruber; Stanley R Hamilton; Matthew F Kalady; Michelle Wan Yee Lau; Karen H Lu; Nancy Roach; Paul J Limburg Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Kathleen M Schmeler; Henry T Lynch; Lee-may Chen; Mark F Munsell; Pamela T Soliman; Mary Beth Clark; Molly S Daniels; Kristin G White; Stephanie G Boyd-Rogers; Peggy G Conrad; Kathleen Y Yang; Mary M Rubin; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Karen H Lu Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Hans Binder; Lydia Hopp; Michal R Schweiger; Steve Hoffmann; Frank Jühling; Martin Kerick; Bernd Timmermann; Susann Siebert; Christina Grimm; Lilit Nersisyan; Arsen Arakelyan; Maria Herberg; Peter Buske; Henry Loeffler-Wirth; Maciej Rosolowski; Christoph Engel; Jens Przybilla; Martin Peifer; Nicolaus Friedrichs; Gabriela Moeslein; Margarete Odenthal; Michelle Hussong; Sophia Peters; Stefanie Holzapfel; Jacob Nattermann; Robert Hueneburg; Wolff Schmiegel; Brigitte Royer-Pokora; Stefan Aretz; Michael Kloth; Matthias Kloor; Reinhard Buettner; Jörg Galle; Markus Loeffler Journal: J Pathol Date: 2017-09-05 Impact factor: 7.996
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059
Authors: Aung Ko Win; Mark A Jenkins; James G Dowty; Antonis C Antoniou; Andrew Lee; Graham G Giles; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Dennis J Ahnen; Stephen N Thibodeau; Graham Casey; Steven Gallinger; Loïc Le Marchand; Robert W Haile; John D Potter; Yingye Zheng; Noralane M Lindor; Polly A Newcomb; John L Hopper; Robert J MacInnis Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-10-31 Impact factor: 4.254
Authors: Pål Møller; Toni T Seppälä; Inge Bernstein; Elke Holinski-Feder; Paulo Sala; D Gareth Evans; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf H Sijmons; Jacqueline Jeffries; Hans F A Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul T Wijnen; Mark A Jenkins; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Laura Renkonen-Sinisalo; Mev Dominguez Valentin; Ian M Frayling; John-Paul Plazzer; Kirsi Pylvanainen; Maurizio Genuardi; Jukka-Pekka Mecklin; Gabriela Moeslein; Julian R Sampson; Gabriel Capella Journal: Gut Date: 2017-07-28 Impact factor: 23.059
Authors: John Burn; Harsh Sheth; Faye Elliott; Lynn Reed; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Möslein; Fiona E McRonald; Lucio Bertario; D Gareth Evans; Anne-Marie Gerdes; Judy W C Ho; Annika Lindblom; Patrick J Morrison; Jem Rashbass; Raj Ramesar; Toni Seppälä; Huw J W Thomas; Kirsi Pylvänäinen; Gillian M Borthwick; John C Mathers; D Timothy Bishop Journal: Lancet Date: 2020-06-13 Impact factor: 79.321